2 recruiting, 1 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Muscle Rigidity: new trials by email Literature Review of Muscle Rigidity trials Research Report on Muscle Rigidity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms Transcranial Electrical Stimulation Device - PARKINSON DISEASE (Disorder) | Phase 1 / Phase 2 | Recruiting | U: The Mind Company | 30 | 2026-01-01 | 2026-01-27 |
| First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) ALN-SNCA, Placebo - Parkinsons Disease | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 46 | 2025-12-05 | 2026-09-21 |
| Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS) IVIg - Muscle Rigidity, Spasm | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 20 | 1996-04-01 | 2006-07-14 |
Parkinson Disease (2) · Tremor (2) · Cognitive Dysfunction (1) · Dyskinesias (1) · Hypokinesia (1) · Mood Disorders (1) · Parasomnias (1) · Primary Dysautonomias (1) · Spasm (1) · Stiff-Person Syndrome (1)
Central Nervous System Diseases (3) · Muscle Hypertonia (3) · Muscular Diseases (3) · Musculoskeletal Diseases (3) · Nervous System Diseases (3) · Neurologic Manifestations (3) · Neuromuscular Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Movement Disorders (2) · Neurodegenerative Diseases (2) · Parkinsonian Disorders (2) · Synucleinopathies (2)
Immunoglobulins, Intravenous (1)
National Institute of Neurological Disorders and Stroke (NINDS) (1) · Regeneron Pharmaceuticals (1) · U: The Mind Company (1)
United States (2) · Canada (1) · Netherlands (1)
2025 (1)